Coya Therapeutics' Alzheimer's Candidate Shows Improved Inflammatory Blood Markers Following Monthly Dosing
1. Coya announced significant results from LD IL-2 Alzheimer’s trial. 2. LD IL-2 showed reduced proinflammatory markers and improved cognitive scores. 3. Monthly LD IL-2 treatment increased Aβ42 levels indicating better amyloid clearance. 4. No serious adverse events reported; treatment was well tolerated. 5. COYA shares rose by 9.48% following positive trial results.